DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic

BMC Infectious Diseases

Jeffrey Lipman³  Steven C Wallis⁵  Therese Starr³  Andrew Rhodes⁴  Jordi Rello²  Philippe Montravers⁸  Claude Martin⁷  Despoina Koulenti¹  George Dimopoulos¹  Jan J De Waele⁶  Jason A Roberts⁵ 

[1]Attikon University Hospital, Athens, Greece

[2]Hospital Vall d’Hebron, Barcelona, Spain

[3]Royal Brisbane and Women’s Hospital, Brisbane, Australia

[4]St George’s Healthcare NHS Trust and St George’s University of London, London, England, UK

[5]Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia

[6]Ghent University Hospital, Ghent, Belgium

[7]Hospital Nord, Marseille, France

[8]Centre Hospitalier Universitaire Bichat-Claude Bernard, AP-HP, Université Paris VII, Paris, France

关键词: Pharmacodynamics;    Pharmacokinetics;    Adverse events;    Bolus dosing;    Extended infusion;    Continuous infusion;    Echinocandin;    Triazole;    Glycopeptide;    βeta-lactam;    Antibiotic;   

Others  :  1175339
DOI  :  10.1186/1471-2334-12-152

 received in 2012-04-11, accepted in 2012-06-28,  发布年份 2012

【 摘 要 】

Background

The clinical effects of varying pharmacokinetic exposures of antibiotics (antibacterials and antifungals) on outcome in infected critically ill patients are poorly described. A large-scale multi-centre study (DALI Study) is currently underway describing the clinical outcomes of patients achieving pre-defined antibiotic exposures. This report describes the protocol.

Methods

DALI will recruit over 500 patients administered a wide range of either beta-lactam or glycopeptide antibiotics or triazole or echinocandin antifungals in a pharmacokinetic point-prevalence study. It is anticipated that over 60 European intensive care units (ICUs) will participate. The primary aim will be to determine whether contemporary antibiotic dosing for critically ill patients achieves plasma concentrations associated with maximal activity. Secondary aims will compare antibiotic pharmacokinetic exposures with patient outcome and will describe the population pharmacokinetics of the antibiotics included. Various subgroup analyses will be conducted to determine patient groups that may be at risk of very low or very high concentrations of antibiotics.

Discussion

The DALI study should inform clinicians of the potential clinical advantages of achieving certain antibiotic pharmacokinetic exposures in infected critically ill patients.

【 授权许可】

   
2012 Roberts et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, et al.: Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007, 2(3):431-439.
• [2]Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA: Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003, 14(4):1022-1030.
• [3]Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115(2):462-474.
• [4]Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596.
• [5]Marshall JC: Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001, 29(7 Suppl):S99-S106.
• [6]Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, et al.: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294(7):813-818.
• [7]Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, et al.: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302(21):2323-2329.
• [8]Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344(10):699-709.
• [9]Lipman J, Udy AA, Roberts JA: Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth Intensive Care 2011, 39:999-1000.
• [10]Pea F, Viale P, Furlanut M: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44(10):1009-1034.
• [11]Roberts JA, Lipman J: Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45(8):755-773.
• [12]Roberts JA, Kruger P, Paterson DL, Lipman J: Antibiotic resistance–what’s dosing got to do with it? Crit Care Med 2008, 36(8):2433-2440.
• [13]Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA: Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005, 39(1):32-38.
• [14]Li C, Du X, Kuti JL, Nicolau DP: Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007, 51(5):1725-1730.
• [15]McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31(4):345-351.
• [16]Sinnollareddy M, Peake SL, Roberts MS, Lipman J, Roberts JA: Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int J Antimicrob Agents 2012, 39(1):1-10.
• [17]Sinnollareddy M, Peake SL, Roberts MS, Playford EG, Lipman J, Roberts JA: Pharmacokinetic evaluation of fluconazole in critically ill patients. Expert Opin Drug Metab Toxicol 2011, 7(11):1431-1440.
• [18]Samtani MN, Flamm R, Kaniga K, Nandy P: Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010, 54(6):2360-2364.
• [19]Roberts JA, Lipman J: Closing the loop - a colistin clinical study to confirm dosing recommendations from PK/PD modeling. Clin Infect Dis Off Publ Infect Dis Soc Am 2012, 54(12):1727-9.
• [20]Roberts JA, Norris R, Paterson DL, Martin JH: Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012, 73(1):27-36.
• [21]Udy AA, Roberts JA, Dewaele JJ, Paterson DL, Lipman J: What’s behind the failure of emerging antibiotics in the critically ill? Understanding the impactof altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012, 39(6):455-7.
• [22]Roberts JA, Field J, Visser A, Whitbread R, Tallot M, Lipman J, Kirkpatrick CM: Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 2010, 54(9):3635-3640.
• [23]Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64(1):142-150.
• [24]Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Piperacillin penetration into tissue of critically ill patients with sepsis–bolus versus continuous administration? Crit Care Med 2009, 37(3):926-933.
• [25]Taccone FS, de Backer D, Laterre PF, Spapen H, Dugernier T, Delattre I, Wallemacq P, Vincent JL, Jacobs F: Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011, 37(6):531-535.
• [26]Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, et al.: Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14(4):R126. BioMed Central Full Text
• [27]Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, Goldrick PB, Lipman J: Meropenem dosing in critically ill patients with sepsis recieving high volume continuous veno-venous hemofiltration. Antimicrob Agents Chemother 2010, 54(7):2974-2978.
• [28]Roberts DM, Roberts JA, Roberts MS, Liu X, Cole CL, Nair P, Lipman J, Bellomo R: Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy – a multicentre pharmacokinetic study. Crit Care Med 2012, 40(5):1523-1528.
• [29]Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J: First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010, 35(2):156-163.
• [30]Lipman J, Wallis SC, Rickard C: Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999, 43(10):2559-2561.
• [31]Lipman J, Wallis SC, Rickard CM, Fraenkel D: Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001, 27(2):363-370.
• [32]Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J: Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010, 65(8):1771-1778.
• [33]Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J: Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36(4):332-339.
• [34]Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26(11):1793-1800.
• [35]Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: A severity of disease classification system. Crit Care Med 1985, 13:818-829.
• [36]Lisboa T, Diaz E, Sa-Borges M, Socias A, Sole-Violan J, Rodriguez A, Rello J: The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia. Chest 2008, 134(6):1208-1216.
• [37]Turnidge JD: The pharmacodynamics of beta-lactams. Clin Infect Dis 1998, 27(1):10-22.
• [38]Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM: Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother 2011, 55(12):5868-5873.
• [39]Faul F, Erdfelder E, Lang AG, Buchner A: G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007, 39(2):175-191.
• [40]Roberts JA, Kirkpatrick CM, Lipman J: Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 2011, 66(2):227-231.